Sign In
Buy RHHBY
$54.64
-0.630 (-1.14%)
At Close: Jul 31, 2026
Roche Holding AG (RHHBY) Q2 2026 Earnings Call Transcript
02:20pm, Friday, 24'th Jul 2026
Roche Holding AG (RHHBY) Q2 2026 Earnings Call Transcript
Roche receives FDA clearance for the cobas® BV/CV assay, enabling fast and highly accurate vaginitis diagnosis
08:30am, Friday, 24'th Jul 2026
/PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its cobas
Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep Momentum
03:21pm, Thursday, 23'rd Jul 2026
RHHBY posts 6% constant-currency sales growth in the first half of 2026 as strong demand for key drugs offsets legacy declines, while FDA pipeline progress supports momentum.
Roche Backs Full-Year View as First-Half Sales Rise
01:40am, Thursday, 23'rd Jul 2026
The drugmaker's sales grew 6% on a constant exchange rate basis and exceeded analysts' expectations, according to a company compiled consensus.
Roche confirms full year targets as first-half sales fall
01:17am, Thursday, 23'rd Jul 2026
Swiss drugmaker Roche confirmed its full-year targets on Thursday as first-half sales fell in Swiss franc terms, dragged down by a strong domestic currency.
Konzernverkäufe stiegen in den ersten sechs Monaten um6% zu konstanten Wechselkursen (CER1; in CHF ausgewiesen -2% und auf USD-Basis28%) aufgrund hoher Nachfrage nach innovativen Medikamenten und Dia
WORCESTER, Mass., July 15, 2026 /PRNewswire/ -- The Hanover Insurance Group, Inc., (NYSE: THG), a leading property and casualty insurance company, announced today that John "Jack" C.
RHHBY's Gazyva Gets FDA Priority Review for Label Expansion
01:10pm, Wednesday, 15'th Jul 2026
Roche wins FDA Priority Review for Gazyva in primary membranous nephropathy, with a decision due by November 2026 after positive phase III data.
The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
12:36pm, Wednesday, 08'th Jul 2026
Markets are being tested again. The AI trade has spent the past several weeks under real pressure, with memory, semiconductor, and neocloud names selling off hard after an extraordinary first half.
Roche Reports Positive Results From Head-to-Head Study on NSCLC Drug
02:46pm, Friday, 03'rd Jul 2026
RHHBY announces positive phase III Krascendo 1 results for divarasib in KRAS G12C NSCLC, showing PFS and OS gains versus approved inhibitors.
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
01:50am, Thursday, 02'nd Jul 2026
Experimental drug, divarasib, showed meaningful improvements in both patients' overall survival and the time they survived without the disease worsening.
Roche Gets FDA Priority Review for Enspryng in Thyroid Eye Disease
03:50pm, Tuesday, 30'th Jun 2026
Roche won FDA priority review for Enspryng in thyroid eye disease, with a decision date in October and phase III data backing the filing.
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
07:45am, Tuesday, 30'th Jun 2026
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
Roche launches Axelios gene sequencer in a bid to loosen Illumina's grip
04:07am, Monday, 29'th Jun 2026
Swiss pharma and diagnostics giant Roche on Monday launched its long-awaited Axelios gene sequencer, in a bid to challenge U.S. firm Illumina's leadership in next-generation sequencing.
Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform
01:00am, Monday, 29'th Jun 2026
AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise their workflows and explore a wider array of appl
